Subcutaneous · FGF21 analog
NNC0194-0499
11 trials in this molecule. Source: ClinicalTrials.gov, as of July 1, 2026.
Trials
11
Active
1
Recruiting
0
Completed
10
Sites
308
Countries
28
Endpoints
118
Composite endpoints
0
Distinct sites and countries across this molecule's trials. A site running several of its trials counts once, matching the map.
Development
Where the program stands
Trials by phase
Phase 1
9
Phase 2
2
Trials by status
Active, not recruiting
1
Completed
10
Evidence coverage
What this asset has been measured on
Endpoints grouped into outcome categories, ranked by how often they are measured across this asset's trials.
Safety / tolerability / PK
67
MASH / liver
20
Cardiometabolic biomarkers
14
Glycemic / diabetes
11
Patient-reported / QoL
3
Weight & body composition
1
Other clinical outcomes
1
Other (unclassified)
1
Most-measured metrics
Top 20 metrics across this asset's endpoints
AUC₀–∞Safety/PK
13
CmaxSafety/PK
12
Treatment-emergent AEs (any)Safety/PK
9
TmaxSafety/PK
8
Half-lifeSafety/PK
5
Triglycerides, changeBiomarker
3
HDL-C, changeBiomarker
2
LDL-C, changeBiomarker
2
AST, changeMASH
2
ELF score, changeMASH
2
ALT, changeMASH
2
Fibrosis ≥1-stage improvement, no MASH worseningMASH
2
CGM time-in-rangeGlycemic
2
CGM time-above-rangeGlycemic
2
CGM time-below-rangeGlycemic
2
Alcohol consumption, changeOther clin.
1
Total cholesterol, changeBiomarker
1
Liver stiffness (VCTE), changeMASH
1
SF-36 physicalPRO/QoL
1
MASH resolution, no fibrosis worseningMASH
1
Trials
Programs for this asset
Every trial for this molecule, with the same search, filters, and sort as the Trials tab.
⌘K
11 of 11